GSK Upbeat on Solid Results - Interviews with CEO and CFO

LONDON, February 7, 2012 /PRNewswire/ --

In an online video interview with MerchantCantos, GlaxoSmithKline CEO Sir Andrew Witty talks about the pharmaceutical group's special dividend, solid results and why the company is so well positioned to continue to deliver.

Sir Andrew said "adversity isn't all downside for everybody" and that the market offered opportunities for companies who had strengthened and had changed their exposure to places of growth.

"This is a time where we should feel optimistic. And certainly at GSK we do feel optimistic.  We feel like are moving into a new era for the company and we now need to focus on absolute disciplined execution to make sure that we take advantage of all of the opportunities that we've worked so hard to try and create for ourselves."

CFO Simon Dingemans admitted there had been some margin pressure in Q4 but that he expected margins to improve gradually. "We expect only a very gradual increase in operating margin, and by that I mean a few tens of basis points and more in 2013 and further thereafter."

The interviews and transcripts are available now on http://www.cantos.com/company/GlaxoSmithKline.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-207-936-1352.

SOURCE GlaxoSmithKline

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.